Big News Gains: Superior Industries International, Inc., Textron (NYSE:TXT), The Kraft Heinz Company (NASDAQ:KHC), Keryx Biopharmaceuticals (NASDAQ:KERX)

OXiGENE, Inc. (NASDAQ:OXGN) shares decreased -0.86% in last trading session and ended the day at $0.58. OXGN has a return on assets of -37.50%. OXiGENE, Inc. (NASDAQ:OXGN) quarterly performance is -35.00%.

OXiGENE Inc (NASDAQ:OXGN) had its target price trimmed by S&P Equity Research from $0.64 to $0.58 in a report issued on Friday morning, Marketbeat reports.

Superior Industries International, Inc. (NYSE:SUP) ended the last trading day at $19.51. Company weekly volatility is calculated as 2.04% and price to cash ratio as 10.08. Superior Industries International, Inc. (NYSE:SUP) showed a weekly performance of 0.72%.

Superior Industries International, Inc. (NYSE:SUP) announced that it will release financial results for the full year and fourth quarter ended December 27th, 2015 on Monday, March 7th, 2016.

On 26 February, Textron Inc. (NYSE:TXT) shares increased 0.12% and was closed at $34.55. TXT EPS growth in last 5 year was 57.50%. Textron Inc. (NYSE:TXT) year to date (YTD) performance is -17.76%.

Textron Inc. (NYSE:TXT) declared a quarterly dividend of $0.02 per share on the company’s Common Stock. All dividends will be paid on April 1, 2016 to shareholders of record as of March 11, 2016.

The Kraft Heinz Company (NASDAQ:KHC) shares increased 3.84% in last trading session and ended the day at $77.84. KHC Gross Margin is 31.30% and its has a return on assets of -0.70%. The Kraft Heinz Company (NASDAQ:KHC) quarterly performance is 5.38%.

The Kraft Heinz Company (NASDAQ:KHC) declared a regular quarterly dividend of $0.575 per share of common stock payable on April 8, 2016 to shareholders of record as of March 18, 2016.

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) caters to the Healthcare space. On the last day of trading company shares ended up at $3.64. Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) distance from 50-day simple moving average (SMA50) is -1.42%.

Keryx Biopharmaceuticals (NASDAQ:KERX) had its target price cut by stock analysts at Citigroup Inc. from $2.50 to $1.80 in a note issued to investors on Friday,StockTargetPrices.com reports. Citigroup Inc.’s target price suggests a potential downside of 48.57% from the company’s previous close.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *